Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.

Hum Vaccin Immunother · 2014 · PMC4896780 · PMID 25424918

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

VE against HPV-31, HPV-33, and HPV-51 incident infection did not reach statistical significance, calculated at 40·4% (–27.2 to 72.9), 34.8% (–51.9 to 72.9), and 6.7% (–41.9 to 38.6), respectively.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.